NURECA

Nureca Share Price

 

Stock Result Declared

 

Start SIP in NURECA

Start SIP

Performance

  • Low
  • ₹288
  • High
  • ₹312
  • 52 Week Low
  • ₹204
  • 52 Week High
  • ₹448
  • Open Price₹300
  • Previous Close₹297
  • Volume48,222
  • 50 DMA₹285.89
  • 100 DMA₹276.77
  • 200 DMA₹272.77

Investment Returns

  • Over 1 Month + 10.49%
  • Over 3 Month + 7.82%
  • Over 6 Month + 21.11%
  • Over 1 Year -23.74%

Smart Investing Starts Here Start SIP with Nureca for Steady Growth!

Invest Now

Nureca Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29.3
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 312
  • P/B Ratio
  • 1.6
  • Average True Range
  • 13.45
  • EPS
  • 4.3
  • Dividend Yield
  • 0
  • MACD Signal
  • 2.39
  • RSI
  • 62.49
  • MFI
  • 63.37

Nureca Financials

Nureca Technicals

EMA & SMA

Current Price
₹311.85
+ 14.85 (5%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹293.03
  • 50 Day
  • ₹285.89
  • 100 Day
  • ₹276.77
  • 200 Day
  • ₹272.77

Resistance and Support

303.8 Pivot Speed
  • R3 344.05
  • R2 327.95
  • R1 319.90
  • S1 295.75
  • S2 279.65
  • S3 271.60

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nureca has an operating revenue of Rs. 130.12 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 36 which is a POOR score indicating inconsistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 127 indicates it belongs to a poor industry group of Medical-Products and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nureca Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-17 Quarterly Results & Others To consider other business matters. per share(20%)Final Dividend
2025-11-28 Buy Back of Shares
2025-11-10 Buy Back of Shares
2025-10-16 Quarterly Results & Others To consider other business matters. per share(20%)Final Dividend
2025-07-15 Quarterly Results
Date Purpose Remarks
2022-02-25 INTERIM Rs.3.00 per share(30%)Interim Dividend
View Nureca Dividend History Arrow

Nureca F&O

Nureca Shareholding Pattern

68.09%
0%
0%
0.09%
0%
29.73%
2.09%

About Nureca

  • NSE Symbol
  • NURECA
  • BSE Symbol
  • 543264
  • Chairman & Managing Director
  • Mr. Saurabh Goyal
  • ISIN
  • INE0DSF01015

Similar Stocks to Nureca

Nureca FAQs

Nureca share price is ₹311 As on 18 January, 2026 | 16:49

The Market Cap of Nureca is ₹311.9 Cr As on 18 January, 2026 | 16:49

The P/E ratio of Nureca is 29.3 As on 18 January, 2026 | 16:49

The PB ratio of Nureca is 1.6 As on 18 January, 2026 | 16:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23